Evidence map›Paper›PMID 39416022›Full record

ArticlebioRxiv : the preprint server for biology2024

Catabolism of extracellular glutathione supplies amino acids to support tumor growth.

Fabio Hecht, Marco Zocchi, Emily T Tuttle, Nathan P Ward, Bradley Smith, Yun Pyo Kang, Juliana Cazarin, Zamira G Soares, Mete Emir Ozgurses, Huiping Zhao and 15 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Fabio HechtDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.ORCID 0000-0001-9110-2587
Marco ZocchiDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.ORCID 0009-0001-3531-3045
Emily T TuttleDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Nathan P WardDepartment of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 33612.
Bradley SmithWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Yun Pyo KangDepartment of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 33612.
Juliana CazarinDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Zamira G SoaresDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Mete Emir OzgursesDepartment of Physiology and Biophysics, University of Illinois College of Medicine, Chicago, IL, USA, 60612.
Huiping ZhaoDepartment of Physiology and Biophysics, University of Illinois College of Medicine, Chicago, IL, USA, 60612.
Colin SheehanBen May Department of Cancer Research, University of Chicago, Chicago, IL, USA, 60637.
Fatemeh AlimohammadiDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Lila D MungerDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Dhvani TrivediDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Gloria AsantewaaDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Sara K Blick-NitkoDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Jason J ZoellerDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA, 02115.
Ying ChenDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA, 06510.
Vasilis VasiliouDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA, 06510.
Bradley M TurnerDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USA, 14620.
Alexander MuirBen May Department of Cancer Research, University of Chicago, Chicago, IL, USA, 60637.
Jonathan L ColoffDepartment of Physiology and Biophysics, University of Illinois College of Medicine, Chicago, IL, USA, 60612.
Joshua MungerWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA, 14620.ORCID 0000-0001-5379-9440
Gina M DeNicolaDepartment of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 33612.
Isaac S HarrisDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA, 14620.ORCID 0000-0002-6855-2763

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Multi-Disciplinary Training Grant in Cancer ResearchT32CA009594 · NCI · UNIVERSITY OF CHICAGO · PI KAY F MACLEOD, Scott A. Oakes · 1989 to 2026
$11.5M
Rochester Partnership to Advance Research and Academic Careers in Deaf ScholarsK12GM106997 · NIGMS · UNIVERSITY OF ROCHESTER · PI BUCKLEY, GERARD J., DEWHURST, STEPHEN · 2015 to 2024
$6.9M
Mouse Models for Alcohol Metabolism and Tissue InjuryR24AA022057 · NIAAA · YALE UNIVERSITY · PI VASILIOU, VASILIS · 2013 to 2022
$4.5M
Investigation of NRF2-Dependent Metabolic LiabilitiesR37CA230042 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI DENICOLA, GINA MARIE · 2018 to 2024
$2.8M
Metabolic modulation by the HCMV UL38 geneR01AI150698 · NIAID · UNIVERSITY OF ROCHESTER · PI JOSHUA C MUNGER · 2020 to 2026
$2.4M
Impact of extracellular glutathione catabolism on triple-negative breast cancerR01CA269813 · NCI · UNIVERSITY OF ROCHESTER · PI Jeevisha Bajaj · 2022 to 2026
$2.2M
Redox Regulation of O-GlcNAcylation Signaling in the Pathogenesis of Alcoholic Fatty Liver DiseaseR01AA028859 · NIAAA · YALE UNIVERSITY · PI Ying Chen · 2022 to 2026
$1.9M
NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA269813NCI NIH HHS R37 CA230042NCI NIH HHS T32 CA009594NIAAA NIH HHS R01 AA028859NIAAA NIH HHS R24 AA022057NIAID NIH HHS R01 AI150698NIGMS NIH HHS K12 GM106997
6 · The paper itself

Abstract

Restricting amino acids from tumors is an emerging therapeutic strategy with significant promise. While typically considered an intracellular antioxidant with tumor-promoting capabilities, glutathione (GSH) is a tripeptide of cysteine, glutamate, and glycine that can be catabolized, yielding amino acids. The extent to which GSH-derived amino acids are essential to cancers is unclear. Here, we find that GSH catabolism promotes tumor growth. We show that depletion of intracellular GSH does not perturb tumor growth, and extracellular GSH is highly abundant in the tumor microenvironment, highlighting the potential importance of GSH outside of tumors. We find supplementation with GSH can rescue cancer cell survival and growth in cystine-deficient conditions, and this rescue is dependent on the catabolic activity of γ-glutamyltransferases (GGTs). Finally, pharmacologic targeting of GGTs' activity prevents the breakdown of circulating GSH, lowers tumor cysteine levels, and slows tumor growth. Our findings indicate a non-canonical role for GSH in supporting tumors by acting as a reservoir of amino acids. Depriving tumors of extracellular GSH or inhibiting its breakdown is potentially a therapeutically tractable approach for patients with cancer. Further, these findings change our view of GSH and how amino acids, including cysteine, are supplied to cells.

Identifiers

PMID39416022
PMCPMC11482906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.